Yaara Ofir-Rosenfeld

Company: STORM Therapeutics Ltd.

Job title: Director, Translational Oncology

Seminars:

Inhibition of METTL3 Activates Innate Immunity Pathways & Reshapes the Tumor Microenvironment 3:30 pm

STC-15 is a potent and selective inhibitor of the RNA methyltransferase METTL3, currently evaluated in a First-in-Human Phase I clinical trial STC-15 leads to formation of dsRNA and induces cancer intrinsic type-I interferon response Ex-vivo and in-vivo efficacy studies in preclinical models demonstrate an immune based MoA leading to a long term tumour regression and…Read more

day: Conference Day 1